Physician profile

Harmohan Singh

Internal Medicine · Kings Mountain, NC

NPI 1487608154

$559.97

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$116.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $168.74 2022
Creo Medical INC. $116.26 2024 Speedboat Ultraslim (Sb1l)
Sunovion Pharmaceuticals INC. $84.97 2019-2020
Novartis Pharmaceuticals Corporation $57.00 2019
Mylan Specialty L.P. $47.35 2019-2020
Astrazeneca Pharmaceuticals Lp $31.40 2019-2022
E.R. Squibb & Sons, L.L.C. $20.07 2019
Merck Sharp & Dohme LLC $18.11 2019
Alkermes, INC. $16.07 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Harmohan Singh

$559.97

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbott Laboratories

https://glasscript.com/doctor/661730/harmohan-singh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.